Obesity, history of weight gain could help predict prostate cancer progression

October 01, 2005

HOUSTON - How heavy a man is at the time he is diagnosed with prostate cancer, as well as his history of weight gain, appear to play significant roles in how aggressive his cancer may become, say researchers at The University of Texas M. D. Anderson Cancer Center.

While a link between weight and initial development of prostate cancer already has been made, this report, published in the Oct. 1 issue of Clinical Cancer Research, is the first to associate a man's body mass at different ages and adult weight gain with the risk of progression after his prostate cancer has been surgically treated.

"These findings support the view that the development of aggressive forms of prostate cancer may be influenced by environmental effects that occur early in life," says the study's lead researcher Sara Strom, Ph.D., an associate professor in the Department of Epidemiology.

Given further validation of the results, Strom suggests a man's history of body weight should be a factor oncologists consider when designing a treatment plan for patients newly diagnosed with prostate cancer.

The data also suggest that interventions such as diet and exercise could be a way to reduce the risk of prostate cancer progression, Strom says.

Researchers based their findings on outcomes from 526 M. D. Anderson prostate cancer patients treated by surgery (prostatectomy). They followed the progress of the patients for an average of 4 1/2 years, checking whether the men entered "biochemical failure" or a rising prostate specific antigen (PSA) level, which can indicate the cancer is advancing.

"After surgery, a patient's PSA should go back to being undetectable, but if it begins to rise, that is an indicator of progression," Strom says. "Thirty percent of men who have biochemical failure will develop a life-threatening cancer metastasis, and so PSA is the only marker we have as yet to predict whose cancer will spread."

Within the group, 18 percent of the patients went into biochemical failure. Researchers then correlated an individual's risk of experiencing that failure with his weight history. They found that: Strom says that it is currently unclear how excess obesity contributes to prostate cancer progression, although leading theories suggest it could be linked to changes in a number of different hormones (such as androgen and growth factors) and/or lifestyle behaviors (such as poor diet and inadequate physical activity). But she adds that "understanding the mechanisms by which weight gain contributes to prostate cancer progression will lead to rationally designed preventive strategies."
-end-
The study was funded by the National Cancer Institute. Co-authors include principal investigator Patricia Troncoso, M.D., Xuemei Wang, Curtis Pettaway, M.D., Christopher Logothetis, M.D., Yuko Yamamura, Kim-Anh Do, Ph.D., and Richard Babaian, M.D.

University of Texas M. D. Anderson Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.